Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Ann-Marie Tindberg, Niels H. Bennike, Aleksandra Lesiak, Farzaneh Safavimanesh et al.
Journal
Dermatology and Therapy
Topics
Dermatology and Skin Diseases
article
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
Ann-Marie Tindberg, Niels H. Bennike, Aleksandra Lesiak, Farzaneh Safavimanesh, Julien Sénéschal, P Reich, Juan-Francisco Silvestre, Norito Katoh, Andrew Blauvelt, Matthew Zirwas, Ketty Peris, Richard G. Langley, H. Chih-Ho Hong, Richard B. Warren, Vivian Laquer, Andreas Wollenberg
article en
Abstract
No abstract available for this paper.
Publication Tag
Dermatology and Therapy
Institutions
Università Cattolica del Sacro Cuore (IT), Centre National de la Recherche Scientifique (FR), Dalhousie University (CA), Capital University (US), University of British Columbia (CA), Universität Hamburg (DE), Manchester Academic Health Science Centre (GB), University Hospital Augsburg (DE), Kyoto Prefectural University of Medicine (JP), Ohio University (US), University Medical Center Hamburg-Eppendorf (DE), Hôpital Saint-André (FR), Medical University of Lodz (PL), North Medical Center (JP), Hospital General Universitario de Alicante Doctor Balmis (ES), NIHR Manchester Biomedical Research Centre (GB), Leo Pharma (Denmark) (DK), Ludwig-Maximilians-Universität München (DE), Dominican College of Blauvelt (US), University of Lübeck (DE)